<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179474</url>
  </required_header>
  <id_info>
    <org_study_id>3110-108-002</org_study_id>
    <nct_id>NCT04179474</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability &amp; Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine</brief_title>
  <official_title>A Phase 1b, Two-Part, Open-Label, Fixed-Sequence, Safety, Tolerability and Drug-Drug Interaction Study Between Single Dose Erenumab or Galcanezumab and Multiple Dose Ubrogepant in Participants With Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide
      safety and tolerability information when ubrogepant and erenumab or ubrogepant and
      galcanezumab are co-administered.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2019</start_date>
  <completion_date type="Actual">December 23, 2019</completion_date>
  <primary_completion_date type="Actual">December 23, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve from time 0 to time t (AUC0-t) ) for ubrogepant</measure>
    <time_frame>17-day treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve from time 0 infinity (AUC0-∞) for ubrogepant</measure>
    <time_frame>17-day treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma drug concentration (Cmax)</measure>
    <time_frame>17-day treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum plasma drug concentration (Tmax) for ubrogepant</measure>
    <time_frame>17-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (λz) for ubrogepant</measure>
    <time_frame>17-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (T½) for ubrogepant</measure>
    <time_frame>17-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance of drug from plasma after extravascular administration (CL/F) for ubrogepant</measure>
    <time_frame>17-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) for ubrogepant</measure>
    <time_frame>17-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants who have potentially clinically significant (PCS) post baseline vital sign values</measure>
    <time_frame>Baseline, 17-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants who have PCS post baseline clinical laboratory values</measure>
    <time_frame>Baseline, 17-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants who have PCS post baseline physical exam values</measure>
    <time_frame>Baseline, 17-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants who have PCS post baseline electrocardiogram (ECG) values</measure>
    <time_frame>Baseline, 17-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse events (safety and tolerability)</measure>
    <time_frame>Baseline, 17-day treatment period</time_frame>
    <description>The number of participants who experience one or more treatment emergent adverse events (TEAE) and incidence of TEAEs</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Part 1, Study Intervention A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose ubrogepant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Study Interventions B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose subcutaneous (SC) injection of erenumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Study Intervention A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose ubrogepant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Study Interventions C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 SC injections of galcanezumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Study Interventions D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose ubrogepant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Study Interventions D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose ubrogepant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ubrogepant</intervention_name>
    <description>Single dose oral administration of ubrogepant</description>
    <arm_group_label>Part 1, Study Intervention A</arm_group_label>
    <arm_group_label>Part 2, Study Intervention A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erenumab</intervention_name>
    <description>Single dose subcutaneous (SC) injection of erenumab</description>
    <arm_group_label>Part 1, Study Interventions B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galcanezumab</intervention_name>
    <description>2 SC injections of galcanezumab</description>
    <arm_group_label>Part 2, Study Interventions C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ubrogepant</intervention_name>
    <description>Repeated once daily oral doses of ubrogepant</description>
    <arm_group_label>Part 1, Study Interventions D</arm_group_label>
    <arm_group_label>Part 2, Study Interventions D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least a 1-year history of migraine with or without aura consistent with a diagnosis
             according to the International Classification of Headache Disorders, 3rd edition,
             (ICHD-3, 2018)

          -  By history, the participant's migraines typically last between 4 and 72 hours if
             untreated or treated unsuccessfully and migraine episodes are separated by at least 48
             hours of headache pain freedom

          -  History of at least 2 migraine attacks per month in the 2 months prior to Screening

          -  Have a sitting pulse rate ≥ 45 beats per minute (bpm) and ≤ 100 bpm during the vital
             sign assessment at the Screening Visit. Clinical site may perform a maximum of 2
             repeats of vital sign measurements if the initial measurement is out of range.

          -  Negative test results for benzoylecgonine (cocaine), methadone, barbiturates,
             amphetamines, benzodiazepines, cannabinoids, opiates, and phencyclidine at the
             Screening Visit and Day -1; unless explained by concomitant medication use (eg,
             opioids prescribed for migraine pain)

          -  Participants willing to minimize the risk of inducing pregnancy for the duration of
             the clinical study and follow-up period

        Exclusion Criteria:

          -  Difficulty distinguishing migraine headache from tension-type or other headaches

          -  Has a history of migraine aura with diplopia or impairment of level of consciousness,
             hemiplegic migraine, or retinal migraine as defined by ICHD-3

          -  Has a current diagnosis of new persistent daily headache, trigeminal autonomic
             cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD 3

          -  Required hospital treatment of a migraine attack 3 or more times in the 6 months prior
             to Screening

          -  Has a chronic non-headache pain condition requiring daily pain medication (with the
             exception of pregabalin)

          -  Previously participated in an investigational study of ubrogepant

          -  Participation in any other clinical investigation using an experimental drug within 30
             days prior to study intervention administration

          -  Participation in a blood or plasma donation program within 60 or 30 days,
             respectively, prior to study intervention administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhijeet Jakate</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QPS</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaulding</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com.</description>
  </link>
  <link>
    <url>http://www.investigatordatabank.org/</url>
    <description>To be considered as a site for current and future Allergan Clinical Trials, please register using the Investigator Databank link.</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ubrogepant</keyword>
  <keyword>erenumab</keyword>
  <keyword>galcanezumab</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erenumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

